To elucidate whether Siglec‐G depletion synergizes with anti‐PD‐1 antibody in tumor immunotherapy, MC38‐OVA bearing mice were treated with activated Siglecg−/− and WT CD8+ T cells plus α‐PD‐1 every three days. The gene discussed is PDCD1; the disease is neoplasm.